Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients.
Yeregui E, Viladés C, Domingo P, Ceausu A, Pacheco YM, Veloso S, Inciarte A, Vidal-González J, Peraire M, Perpiñán C, Falcó V, Masip J, Alba V, Vargas M, Martí A, Reverté L, Mallolas J, Vidal F, Peraire J, Rull A. Yeregui E, et al. Among authors: inciarte a. EBioMedicine. 2020 Dec;62:103077. doi: 10.1016/j.ebiom.2020.103077. Epub 2020 Nov 6. EBioMedicine. 2020. PMID: 33166788 Free PMC article.
A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine.
de Lazzari E, Lonca M, Rojas J, Gonzalez-Cordon A, Blanch J, Inciarte A, Tricas A, Rodriguez A, Martinez-Rebollar M, Laguno M, Mallolas J, Sanchez-Palomino S, Plana M, Blanco JL, Martinez E. de Lazzari E, et al. Among authors: inciarte a. AIDS. 2019 Oct 1;33(12):1891-1896. doi: 10.1097/QAD.0000000000002311. AIDS. 2019. PMID: 31335805 Clinical Trial.
Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study.
Inciarte A, Gonzalez-Cordon A, Rojas J, Torres B, de Lazzari E, de la Mora L, Martinez-Rebollar M, Laguno M, Callau P, Gonzalez-Navarro A, Leal L, Garcia F, Mallolas J, Mosquera M, Marcos MA, Ambrosioni J, Miro JM, Martinez E, Blanco JL; (on behalf the COVID-19 in HIV Investigators). Inciarte A, et al. AIDS. 2020 Oct 1;34(12):1775-1780. doi: 10.1097/QAD.0000000000002643. AIDS. 2020. PMID: 32773471 Free PMC article.
Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
Laguno M, Martínez-Rebollar M, Casanova M, de Lazzari E, González-Cordón A, Torres B, Inciarte A, Mora L, Ugarte A, Ambrosioni J, Blanco JL, Martínez E, Mallolas J. Laguno M, et al. Among authors: inciarte a. Clin Microbiol Infect. 2022 Apr;28(4):610.e1-610.e7. doi: 10.1016/j.cmi.2021.08.019. Epub 2021 Aug 28. Clin Microbiol Infect. 2022. PMID: 34464735 Free article.
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Llibre JM, Domingo P, Falcó V, Imaz A, Cortés C, Force L, Letang E, Vilaró I, Casabona J, Miro JM; PISCIS study group. Nomah DK, et al. Lancet HIV. 2021 Nov;8(11):e701-e710. doi: 10.1016/S2352-3018(21)00240-X. Epub 2021 Oct 13. Lancet HIV. 2021. PMID: 34655549 Free PMC article.
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Casabona J, Domingo P, Navarro J, Imaz A, Deig E, Navarro G, Llibre JM, Miro JM; PISCIS study group. Nomah DK, et al. J Antimicrob Chemother. 2022 Jul 28;77(8):2265-2273. doi: 10.1093/jac/dkac177. J Antimicrob Chemother. 2022. PMID: 35678461 Free PMC article.
A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; RALPEP Study Group. Leal L, et al. Among authors: inciarte a. J Antimicrob Chemother. 2016 Jul;71(7):1987-93. doi: 10.1093/jac/dkw049. Epub 2016 Mar 18. J Antimicrob Chemother. 2016. PMID: 26994089 Clinical Trial.
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; MARAVIPEP Study Group. Leal L, et al. Among authors: inciarte a. J Antimicrob Chemother. 2016 Jul;71(7):1982-6. doi: 10.1093/jac/dkw048. Epub 2016 Mar 18. J Antimicrob Chemother. 2016. PMID: 26994091 Clinical Trial.
Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study.
Martínez-Rebollar M, De La Mora L, Campistol M, Cabrera B, Bagué A, De Lazzari E, Torres B, González-Cordón A, Inciarte A, Ambrosioni J, Martínez E, Blanco JL, Forns X, Blanch J, Mallolas J, Laguno M. Martínez-Rebollar M, et al. Among authors: inciarte a. Infect Dis Ther. 2021 Sep;10(3):1253-1266. doi: 10.1007/s40121-021-00448-0. Epub 2021 Apr 29. Infect Dis Ther. 2021. PMID: 33914265 Free PMC article.
70 results